Abstract
Molecular imaging of brain structures by highly sensitive non-invasive techniques offers unique possibilities in the understanding of physiological and pathological processes in the central nervous system. In particular, the quantitative analysis by positron emission tomography (PET) of α7 nicotinic acetylcholine receptors (α7 nAChR), which are involved in different signalling pathways in the brain, is assumed to provide important information on the relation between receptor dysfunction and the pathogeneses of neuropsychiatric brain diseases, but the applicability of this imaging approach is still hampered due to insufficient imaging agents. This paper presents the recent efforts made to develop PET radiotracers targeting α7 nAChR as well as the current state of the evaluation of the most promising radiolabelled compounds in animal models and humans.
Keywords: drug design, molecular imaging, neurodegeneration, nicotine, orthosteric ligand, acetyl-choline, tomography, positron, radioligands, radiotracers
Current Drug Targets
Title:Development of Radioligands for the Imaging of α7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography
Volume: 13 Issue: 5
Author(s): Peter Brust, Dan Peters, Winnie Deuther-Conrad
Affiliation:
Keywords: drug design, molecular imaging, neurodegeneration, nicotine, orthosteric ligand, acetyl-choline, tomography, positron, radioligands, radiotracers
Abstract: Molecular imaging of brain structures by highly sensitive non-invasive techniques offers unique possibilities in the understanding of physiological and pathological processes in the central nervous system. In particular, the quantitative analysis by positron emission tomography (PET) of α7 nicotinic acetylcholine receptors (α7 nAChR), which are involved in different signalling pathways in the brain, is assumed to provide important information on the relation between receptor dysfunction and the pathogeneses of neuropsychiatric brain diseases, but the applicability of this imaging approach is still hampered due to insufficient imaging agents. This paper presents the recent efforts made to develop PET radiotracers targeting α7 nAChR as well as the current state of the evaluation of the most promising radiolabelled compounds in animal models and humans.
Export Options
About this article
Cite this article as:
Peter Brust, Dan Peters, Winnie Deuther-Conrad , Development of Radioligands for the Imaging of α7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800398955
DOI https://dx.doi.org/10.2174/138945012800398955 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thioredoxin, Glutathione and Related Molecules in Tumors of the Nervous System
Current Medicinal Chemistry RBM15 Functions in Blood Diseases
Current Cancer Drug Targets From Test Tube to Clinical Trial; Promising Herbs with NF-κB and COX- 2 Activity
Current Immunology Reviews (Discontinued) Features Identification for Phenotypic Classification Based on Genes and Gene Pairs
Current Bioinformatics The Role of Melatonin in Pancreatic Protection: Could Melatonin be Used in the Treatment of Acute Pancreatitis?
Current Pharmaceutical Design Cytochrome P450-based Gene Therapy for Cancer Treatment: From Concept to the Clinic
Current Drug Metabolism Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry <i>Circular RNA NF1-419</i> Inhibits Proliferation and Induces Apoptosis by Regulating Lipid Metabolism in Astroglioma Cells
Recent Patents on Anti-Cancer Drug Discovery Association of Hypothyroidism with Body Mass Index, Systolic Blood Pressure and Proteinuria in Diabetic Patients: Does treated Hypothyroidism with Thyroxine Replacement Therapy Prevent Nephropathy/Chronic Renal Disease?
Current Diabetes Reviews Analytical and Pharmacological Aspects of Therapeutic Drug Monitoring of mTOR Inhibitors
Current Drug Metabolism Heme Oxygenase-1: A Fundamental Guardian Against Oxidative Tissue Injuries in Acute Inflammation
Mini-Reviews in Medicinal Chemistry Editorial from Guest Editor [Hot topic: Community-Acquired Pneumonia – Evolving Changes in Our Understanding and How This Impacts on Management (Guest Editor: Grant Waterer)]
Current Respiratory Medicine Reviews Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Current Cancer Drug Targets QSAR Approaches Applied to Antidepressants Induced Neurogenesis - in vivo and in silico Applications
Mini-Reviews in Medicinal Chemistry The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?
Current Gene Therapy Drug Development and the Importance of Ethnicity: Lessons from Heart Failure Management and Implications for Hypertension
Current Pharmaceutical Design Novel Pentapeptide Activators of Mammalian and Mushroom Tyrosinase
Current Topics in Medicinal Chemistry Regulation of Apoptosis and Cell Survival by Resveratrol
Mini-Reviews in Organic Chemistry Histone Post-translational Modifications to Target Memory-related Diseases
Current Pharmaceutical Design Materials Degradation in PVC Medical Devices, DEHP Leaching and Neonatal Outcomes
Current Medicinal Chemistry